BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population

 
• By Jessica Merrill

The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.

applause
Tislelizumab improved overall survival in gastric cancer • Source: Shutterstock

More from Anticancer

More from Therapy Areas